2022 World Conference on Lung Cancer (ePosters)-EP05.01-003. First Real-World Data on Unresectable Stage III NSCLC Patients Treated with Durvalumab after Chemoradiotherapy in Asia Area

EP05.01-003. First Real-World Data on Unresectable Stage III NSCLC Patients Treated with Durvalumab after Chemoradiotherapy in Asia Area

Back to course

Pdf Summary

A retrospective study was conducted in Taiwan to examine the effectiveness and side effects of durvalumab as consolidation therapy in patients with unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy. A total of 106 patients were included in the study. The primary outcome measured was progression-free survival (PFS), and subgroup analyses were performed based on the genetic status of epidermal growth factor receptor (EGFR) and the expression levels of programmed death ligand 1 (PD-L1).<br /><br />The results showed that the median PFS for all patients was 11.75 months, with PFS rates of 49.06% at 12 months and 44.34% at 18 months. Patients with EGFR wild-type had longer PFS compared to those with EGFR mutations, with a 12-month PFS rate of 56% versus 33%, respectively. The positivity of PD-L1 did not affect PFS, with a 12-month PFS rate of 44% versus 38% for PD-L1 positive and negative patients, respectively.<br /><br />The most common adverse event observed was pneumonitis, which occurred in 20.75% of patients. Other adverse events of special interest included endocrine disorders, rash, dermatitis, hepatitis, increased blood creatinine, transaminases, diarrhea, and radiation-induced lung fibrosis.<br /><br />The study concluded that in this Asian population, patients with EGFR wild-type had longer PFS compared to those with EGFR mutations. The expression levels of PD-L1 did not affect PFS. However, further investigation is needed to determine if factors such as delayed initiation of durvalumab are related to survival outcomes. The authors noted that subgroup analysis should be interpreted with caution due to the small population size of each subgroup and potential confounding factors.<br /><br />Overall, these findings provide real-world data on the use of durvalumab as consolidation therapy in Asian patients with unresectable stage III NSCLC after chemoradiotherapy and highlight the need for further research in this area.

Asset Subtitle

ChihHsi Kuo

Meta Tag

Speaker ChihHsi Kuo

Topic Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

Keywords

retrospective study

Taiwan

durvalumab

consolidation therapy

NSCLC

progression-free survival

EGFR

PD-L1

adverse event

Asian population